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Beef fat is a natural source of trans (t) fatty acids, and is typically enriched with either t10-18:1 or t11-
18:1. Little is known about the bioactivity of individual t-18:1 isomers, and the present study compared
the effects of t9-18:1, cis (c)9-18:1 and trans (t)-18:1 fractions isolated from beef fat enriched with either
t10-18:1 (HT10) or t11-18:1 (HT11). All 18:1 isomers resulted in reduced human liver (HepG2) cell via-
bility relative to control. Both c9-18:1 and HT11were the least toxic, t9-18:1had dose response increased
toxicity, and HT10 had the greatest toxicity (Po0.05). Incorporation of t18:1 isomers was 1.8–2.5 fold
greater in triacylglycerol (TG) than phospholipids (PL), whereas Δ9 desaturation products were selec-
tively incorporated into PL. Culturing HepG2 cells with t9-18:1 and HT10 increased (Po0.05) the Δ9
desaturation index (c9–16:1/16:0) compared to other fatty acid treatments. HT10 and t9-18:1 also in-
creased expression of lipogenic genes (FAS, SCD1, HMGCR and SREBP2) compared to control (Po0.05),
whereas c9-18:1 and HT11 did not affect the expression of these genes. Our results suggest effects of
HT11 and c9-18:1 were similar to BSA control, whereas HT10 and t-9 18:1 (i.e. the predominant trans
fatty acid isomer found in partially hydrogenated vegetable oils) were more cytotoxic and led to greater
expression of lipogenic genes.
Crown Copyright & 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Consumption of trans (t) fatty acids have been associated with
numerous adverse effects such as increased plasma LDL-choles-
terol/HDL-cholesterol ratio, inflammation, insulin resistance, en-
dothelial dysfunction and oxidative stress [1,2]. The main dietary
source of trans fatty acids has been partially hydrogenated vege-
table oil (PHVO), which can contain up to 60% trans fatty acids. The
trans fatty acids in PHVO are mainly in the form of trans-evier B.V. This is an open access a
PE, silver ion solid phase ex-
y acid synthase; HMGCR, 3-
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, sterol regulatory element-
t-binding protein-2; t, trans;
an).octadecenoic acid (t-18:1), representing 90–95% of total trans fatty
acids in PHVO [3]. Among these, t9-18:1 (elaidic acid) and t10-18:1
are typically the first and second major isomers, making up on
average about 28% and 21% of total t-18:1 respectively [4]. Inter-
nationally, reduction in PHVO in the food supply has become a
priority, and this is to the point where PHVO are no longer gen-
erally recognized as safe in the USA, and food manufactures have
been given three years to take them out of their products [5]. This
leaves ruminant meat and milk as the major source of t18:1 in
human diets.
In ruminant animals (e.g. sheep, cattle, goats), t18:1 isomers are
produced by rumen microbes during biohydrogenation of dietary
polyunsaturated fatty acids (PUFA), and these can be incorporated
into meat and milk [6]. When cattle are fed diets with a high
forage to grain ratio, t11-18:1 is typically 50–70% of t-18:1 isomers,
but when a low forage to grain diet is fed, ruminal biohy-
drogenation pathways shift towards t10-18:1 production [7]. The
most concentrated trans fatty acid in ruminant products is,rticle under the CC BY-NC-ND license
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this has made it difficult to interpret their human health effects. In
contrast to PHVO, epidemiological studies indicate ruminant trans
fatty acids are not associated with increased risk for coronary
heart disease [8–11], and several animal and cell culture studies
have noted positive health effects of t11-18:1. Clinical trials,
however, have shown trans fatty acids from both PHVO and ru-
minant fats have adverse effects on blood lipids and lipoproteins
[12,13].
Studying the effects of t18:1 isomers in cell culture is made
difficult because some isomers (e.g. t9- and t11-18:1) are com-
mercially available, while others (e.g. t10-18:1) are not. In order to
clarify effects of ruminant products with differing trans fatty acid
composition, a limited number of animal feeding studies have
included dairy products enriched with different t-18:1 isomers
[14,15]. Changes in the t-18:1 profile, however, may have led to
confounding effects due to changes in the saturated fatty acid
(SFA) and cis-monounsaturated fatty acid (c-MUFA) contents. To
alleviate confounding effects of other fatty acids, we developed
silver-ion chromatography techniques to isolate t-18:1 fractions
and individual t-18:1 isomers in quantities sufficient to test their
metabolism and bioactivity in cell culture [16]. The objective of the
present experiment was to compare the effects of t18:1 fractions
from beef fat enriched with t10-18:1 (HT10) or t11-18:1 (HT11)
with t9-18:1 (the major t18:1 isomer in PHVO) and c9-18:1 (oleic
acid) in liver cell culture (HepG2). We chose liver cells because of
their central role in the metabolism of cis and trans fatty acids
including β-oxidation, Δ9 desaturation and lipoprotein secretion
[17]. In addition, the adverse effects of trans fatty acids from PHVO
on blood lipoproteins have been suggested to be mediated in part
via modulation of hepatic lipogenic gene expression [18,19]. We
hypothesized that beef t-18:1 fractions with different t-18:1 iso-
mer profiles would have distinct effects on HepG2 cells, specifi-
cally in terms of cell viability, lipogenic gene expression, and in-
corporation of t-18:1 isomers into cell triacylglycerol (TG) and
phospholipid (PL) fractions.2. Materials and methods
2.1. Fatty acid treatments
The HT11 and HT10 fractions were isolated from banked
backfat samples collected from cattle fed forage (hay) and barley
grain-based diets respectively. Diets included supplements rich in
18:2n-6 to increase the content of t18:1 fatty acids in beef fat. The
distribution of t-18:1 isomers of the HT11 and HT10 fractions are
presented in Table 1. Trans-18:1 fractions were isolated using sil-
ver ion (Agþ) solid phase extraction [16]. Briefly, fat was freeze
dried, dissolved in toluene and methylated using 0.5 M sodiumTable 1
Composition of t-18:1 fractions used for HeG2 culture.
Fatty acid (%) HT10a HT11a
t6–t8-18:1 7.4 4.0
t9-18:1 5.7 4.1
t10-18:1 69.3 2.9
t11-18:1 7.6 65.4
t12-18:1 1.8 6.9
t13/t14-18:1 3.0 6.8
t15-18:1 0.7 5.1
t16-18:1 0.4 2.9
a HT11¼t-18:1 fraction enriched with t11-18:1 from a beef cattle fed a grass-
hay based diet. HT10¼t-18:1 fraction enriched with t10-18:1 from a beef cattle fed
a barely grain based diet.methoxide [20]. The resulting fatty acid methyl esters were dis-
solved in hexane and applied to Discoverys Agþ-SPE columns
(750 mg/6 ml, Supelco, Bellefonte, PA, USA). Saturated fatty acids
(SFA) were eluted with 10 ml of hexane and the t-18:1 fraction was
collected with 10 ml 98:2 hexane: acetone (v/v). The t-18:1 FAME
were then saponified to free fatty acids using 0.3 M methanolic
potassium hydroxide [21].
Individual 18:1 isomers including t9-18:1 and c9-18:1 were
purchased from Nu-Chek Prep, Inc. (Elysian, MN, USA). Individual
fatty acids and t18:1 fractions were complexed with fatty acid free
bovine serum albumin (BSA) at a 4:1 M ratio (4 mM fatty acid:
1 mM BSA) as described by Evans et al. [22]. Fatty acid-BSA com-
plexes were then diluted in cell culture media to provide desired
final fatty acid concentrations (100 or 200 μM).
2.2. Cell viability
To test viability, cells were cultured with growth medium
containing 5% FBS and supplemented with 100 μM or 200 μM of
fatty acids for 96 h. Cell proliferation was assessed using CellTiter-
Blue cell viability assay (Promega, Madison, WI). Briefly, HepG2
cells were seeded in 96-well plates (1000 cells/well) and al-
lowed to attach before 300 μl of medium containing 100 or
200 μM of fatty acid treatment was added. At 0 h, 24 h, 48 h, 72 h
and 96 h growth medium including fatty acid treatments was re-
placed with 100 μl/well serum free medium plus 20 μl/well Cell-
Titer 96s AQueous One Solution reagent (Promega, Madison, WI).
After 1.5 h incubation at 37 °C in 6% CO2, the absorbance at
490 nm was recorded using a SpectraMax M5 plate reader (Mo-
lecular Devices, Sunnyvale, CA). The viability results for fatty acid
treatments were expressed relative to BSA control.
2.3. Culture conditions for gene expression and fatty acid analyses
Human hepatoma HepG2 cells (ATCC; Rockville, MD, USA) were
seeded at a density of 1105 cells per well (9.6 cm2) in 6-well
plates, and cultured at 37 °C in 6% CO2 in a growth medium con-
taining Eagle’s minimum essential medium (EMEM; ATCC) sup-
plemented with 10% fetal bovine serum (FBS, Sigma Aldrich, St.
Louis, MO, USA) and 1% penicillin-streptomycin (Life Technologies,
Burlington, ON, Canada). Cell culture medium was changed every
two days, and at 24 h post-confluence, FBS was removed from the
medium and cells were treated with 100 μM of the fatty acid-BSA
complex for 24 h, and cells were used for fatty acid and gene ex-
pression analyses. Control cells were cultured with an equal vo-
lume of BSA (vehicle control). Two wells of cells were cultured per
treatment per experiment, and the experiment was repeated three
times.
2.4. RNA extraction, reverse transcription and quantitative PCR
Total RNA was extracted from HepG2 cells using the Aurum
total RNA fatty and fibrous tissue kit (Bio-Rad Laboratories, Mis-
sissauga, ON, Canada). The RNA concentrations were determined
by absorbance at 260 nm using a Nanodrop ND-1000 spectro-
photometer (Thermo Fisher Scientific, Wilmington, DE), and the
RNA purity was evaluated using the 260:280 and 260:230 absor-
bance ratios to ensure both ratios were between 1.8 and 2.1. In-
tegrity of RNA was confirmed by the presence of intact RNA sub-
units 28S and 18S using an automated capillary electrophoresis
QIAxcel system (Qiagen, Hilden, Germany). cDNA was synthesized
from 1 μg of RNA using M-MLV reverse transcriptase kit (Invitro-
gen, Carlsbad, CA, USA) in the presence of random hexamer pri-
mers and Ribonuclease Inhibitor (Invitrogen) in a total reaction
volume of 20 μl. Real-time PCR analysis was performed using a
Stratagene Mx3005P QPCR system (Agilent Technologies) using
Table 2
Gene specific forward and reverse primer sequences of genes used for Real-Time PCR.
Gene Forward primer (5′–3′) Reverse primer (5′–3′)
ACC GAGGGCTAGGTCTTTCTGGAAG CCACAGTGAAATCTCGTTGAGA
FAS TATGCTTCTTCGTGCAGCAGTT GCTGCCACACGCTCCTCTAG
SCD1 CTCCACTGCTGGACATGAGA AATGAGTGAAGGGGCACAAC
HMGCR TACCATGTCAGGGGTACGTC CAAGCCTAGAGACATAAT
SREBP1c GCGGAGCCATGGATTGCAC CTCTTCCTTGATACCAGGCCC
SREBP2 CGCCACCTGCCCCTCTCCTTCC TGCCCTGCCACCTATCCTCTCACG
β-actin AAAGACCTGTACGCCAACACAGTGCTGTCTGG CGTCATACTCCTGCTTGCTGATCCACATCTGC
ACC: acetyl-CoA carboxylase; FAS: fatty acid synthase; SCD1: stearoyl-CoA desaturase-1; HMGCR:
3-Hydroxy-3-Methylglutaryl-CoA reductase, SREBP1c: sterol regulatory element-binding protein-1c;
SREBP2: sterol regulatory element-binding protein-2.
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denaturation at 95 °C for 15 s, and annealing/extension at 60 °C for
60 s, repeated for 40 cycles. This was followed by a melt curve
analysis as per the manufacturer's settings to ensure specific am-
plification. Primers were designed using primer 3.0 software or
taken from the literature (Table 2).
Samples were run in triplicate in 96-well plates, and each 20 μl
reaction contained 6 μl cDNA diluted at 1:50, 0.4 μl of each for-
ward and reverse primes (10 mM), 8 μl Green-2-Go qPCR Mas-
termix (BioBasic, Markham, ON, Canada), and 5.2 μl of nuclease-
free water. Relative mRNA expression was calculated using ΔCt
method with β-actin as internal control gene. Briefly, target gene
cycle threshold (Ct) values was normalized to that of β-actin using
2ΔCt where ΔCt¼Ct target geneCt β-actin. Statistical analysis
was performed on 2–ΔCt data and the results were expressed as
fold change relative to control [23].2.5. Fatty acid analysis
Cell lipids were extracted using hexane:isopropanol (3:1) [24]
and dried under N2(g). The lipid extracts were then dissolved in
chloroform and subjected to thin layer chromatography (TLC)
using silica G TLC plates and a mobile phase consisting of hexane:
diethyl ether:acetic acid (85:15:1 by vol). To assist in lipid class
identification, plates were also spotted with a standard containing
phospholipid (PL), cholesterol ester, triacylglycerol (TG) and free
fatty acids (Nu-Chek Prep. Inc. Elysian, MN, USA). After develop-
ment, plates were dried under N2(g), plates were sprayed with
2′,7′-dichlorofluorescein in methanol, and lipids were visualized
under UV light. The spots containing TG and PL were scraped into
pyrex culture tubes (16 mm1.27 mm) with Teflon coated liners,
and methylated using 0.5 M sodium methoxide (15 min at 50 °C)
with the inclusion of c10-17:1 as an internal standard (Nu-Chek
Prep). Resulting fatty acid methyl esters were analysed by gas
chromatography using a CP-Sil88 column (100 m, 25 mm ID,
0.2 mm film thickness) using a CP-3800 gas chromatograph
equipped with a flame ionization detector and a 8400-series au-
tosampler (Varian Inc., Walnut Creek, CA, USA). Hydrogen was
used as the carrier gas (1 ml/min initial flow rate, head pressure
25 psi) and the injection port was set at 250 °C, while the detector
was set at 260 °C. The temperature program was as follows: initial
temperature at 45 °C for 4 min, raised to 175 °C at 13 °C/min and
held for 27 min, then to 215 °C at 4.0 °C/min, and finally held at
this temperature for 35 min [27]. Individual peaks were identified
using reference standards (GLC-603, Nu-Chek Prep. Inc., Elysian,
MN, USA) and peak order and retention times reported in the
literature [25–27]. The c9-16:1/16:0 and c9-18:1/18:0 ratios were
used to estimate stearoyl-CoA desaturase-1 (SCD1) activity.2.6. Statistical analysis
Data were analysed using the mixed models procedure of SAS
(v 9.3; SAS Institute, Cary, IN, USA) with treatment as the fixed
effect and experimental replicate as the random effect. The means
were considered to be significantly different at Po0.05 using the
Tukey-Kramer multiple comparison test. Data are expressed as
means7SEM.3. Results
3.1. Cell viability
The viability of HepG2 cells in the presence of 100 mM or
200 mM of fatty acid treatments are shown in Fig. 1. Culturing cells
with all 18:1 treatments reduced cell viability over 96 h of in-
cubation compared to BSA control. However, only cells cultured
with HT10 or t9-18:1 showed significant inhibitory (Po0.05) re-
sponses to increased fatty acid concentration (i.e. from 100 mM to
200 mM) occurring from 48 h to 96 h of incubation, and cytotoxic
effects of HT10 were more pronounced than t9-18:1.
3.2. SFA, cMUFA and PUFA composition and Δ9 desaturation indices
Fatty acid compositions of HepG2 cell TG and PL are presented
in Table 3. Treating cells with t9-18:1, HT10 or HT11 reduced
(Po0.05) SFA (e.g. 16:0 and 18:0) and c-MUFA contents comparted
to control cells and changes were more pronounced in TG than in
PL. Culturing cells with c9-18:1 increased its content (Po0.05)
mainly at the expense of other c-MUFA (e.g. c11-18:1 and c9-16:1)
and SFA, and this effect was more evident in TG than PL. The
percentage of n-6 and n-3 PUFA in TG and PL fractions were not
affected by any fatty acid treatment. Treatment of cells with t9-
18:1 or HT10 increased (Po0.05) the c9-16:1/16:0 ratio in PL
compared to c9-18:1 and HT11, but fatty acid treatments had no
effect on c9-16:1/16:0 ratios in TG. As expected, treatment of cell
with c9-18:1 led to the greatest c9-18:1/18:0 ratios in both TG and
PL. The c9-18:1/18:0 ratio was increased in PL of cells treated with
t9-18:1 or HT10 compared to control cells (Po0.05), but was no
change was detected with HT11.
3.3. Incorporation of t18:1 isomers and their Δ9 desaturation
products
The content of t18:1 isomers and their Δ9 desaturation pro-
ducts in TG and PL fractions are presented in Table 4. All fatty acids
with a trans double bond in cellular lipids originated from exo-
genous sources (i.e. t18:1 treatments) because of their absence
from both BSA control and c9-18:1 treated cells. All t18:1 isomers
were incorporated to a much greater extent (1.8–2.5 times) into
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Fig. 1. Viability of HepG2 cells cultured with 100 mM (black) or 200 mM (gray) of cis(c)9-18:1, trans(t)9-18:1, HT11 or HT10 during 96 h incubation. Values (mean7SE; n¼6/
treatment) are expressed as percentage changes relative to the BSA control. HT11¼beef t-18:1 fraction enriched with t11-18:1; HT10¼beef t-18:1 fraction enriched with t10-
18:1.
Table 3
Fatty acid composition (molar %) and Δ9 desaturation ratios in triacylglycerol (TG)
and phospholipids (PL) of HepG2 cells cultured with 100 mM of cis-9 18:1, trans-9
18:1, HT11 and HT10 for 24 h.
Fatty acid1 Control c9-18:1 t9-18:1 HT112 HT102 SEM3
TG
16:0 30.20a 14.90b 14.21b 18.27b 14.39b 2.00
c9-16:1 7.54a 4.44b 5.21b 5.24b 4.03b 0.50
18:0 7.66a 2.76b 2.64b 3.46b 3.50b 0.52
c9-18:1 23.53b 61.14a 12.09c 11.85c 10.92c 1.38
c11-18:1 21.03a 8.90b 7.75b 8.47b 6.76b 0.61
18:2n6* 0.18a 0.21a 0.26a 0.26a 0.27a 0.07
20:4n-6 o0.01 o0.01 o0.01 o0.01 o0.01 o0.01
20:5n-3 o0.01 o0.01 o0.01 o0.01 o0.01 o0.01
22:6n-3 o0.01 o0.01 o0.01 o0.01 o0.01 o0.01
c9-16:1/16:0 0.26a 0.30a 0.37a 0.30a 0.28a 0.03
c9-18:1/18:0 3.28b 22.40a 4.77b 3.66b 3.16b 0.67
PL
16:0 22.17a 19.71ab 12.35d 18.24bc 14.85cd 0.91
c916:1 12.10a 6.73b 8.03b 7.85b 8.65b 0.56
18:0 8.21a 7.34ab 4.32d 5.28cd 4.93bc 0.36
c9-18:1 22.96b 43.36a 15.82c 14.00c 16.69c 0.63
c11-18:1 17.35a 9.90b 9.86b 9.41b 9.66b 0.25
18:2n6* 1.51a 1.29a 1.55a 1.22a 1.49a 0.10
20:4n-6 3.69a 3.20a 3.65a 3.08a 3.63a 0.18
20:5n-3 0.07a 0.04a 0.07a 0.10a 0.03a 0.04
22:6n-3 2.01a 1.63a 1.74a 1.45a 1.72a 0.14
c9-16:1/16:0 0.55ab 0.34b 0.65a 0.43b 0.60a 0.02
c9-18:1/18:0 2.89c 5.93a 3.70b 2.66c 3.52b 0.14
a–dMeans within a row not sharing common letters are significantly different
(Po0.05).
* 18:2n6 is co-eluting with c9,t16-18:2.
1 c¼cis; t¼trans.
2 HT11¼beef t-18:1 fraction enriched with t11-18:1; HT10¼beef t-18:1 fraction
enriched with t10-18:1.
3 Standard error of the mean.
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Cells treated with HT10 or t9-18:1 had 140% more Σt-18:1 in
TAG than cells treated with HT11 (Po0.05). In PL, cells treated
with t9-18:1 had the greatest Σt-18:1 (34%) followed by HT10
(26%) and HT11 (19%). Treatment of cells with HT10 and HT11 led
to the incorporation of several minor t18:1 isomers due to their
presence in treatment fractions, but minor t18:1 isomers were not
found when cells were treated with (pure) t9-18:1.
Several t18:1 (e.g. t11-, t12-, t13/t14- and t15-18:1) in HT10 and
HT11 treated cells underwent Δ9 desaturation, and these were
detected in both TG and PL. During GC, these were detected as c9,
t11-18:2 and two peaks with co-eluting isomers (c9,t13-/c9,t14-
18:2 and c9,t12-/c9,t15-18:2). In contrast to t18:1 isomers, which
were preferentially incorporated into TG, the t18:1 derived Δ9
desaturation products tended to accumulate in PL. Cells treated
with HT11 had the greatest content of t18:1 derived Δ9 desa-
turation products in TG and PL (11.9% and 14.3% respectively),
followed by HT10 treated cells (2.0% and 3.6% respectively), while
t9-18:1 treated cells were devoid of t18:1 derived Δ9 desaturation
products.
3.4. mRNA expression of key genes involved in fatty acid and cho-
lesterol synthesis
The relative mRNA abundance of key genes involved in de novo
fatty acid synthesis (ACC, FAS), Δ9 desaturation (SCD1), choles-
terol synthesis (HMGCR) and key transcriptional regulators of li-
pogenesis (SREBP1c) and cholesterol synthesis (SREBP2) are
shown in Fig. 2. Culturing cells with t9-18:1 or HT10 similarly
increased (Po0.05) mRNA expression of FAS, SCD1 and SREBP2
compared to control (BSA) and c9-18:1, but culturing with HT11
did not affect expression of these genes. The expression of SREBP1-
c was only affected (Po0.05) in t9-18:1 treated cells which was
increased compared to control (BSA) and other fatty acid
treatments.
Table 4
The content (molar %) of t-18:1 isomers and their Δ9 desaturation in triacylglycerol
(TG) and phospholipid (PL) fractions of HepG2 cells cultured with 100 mM of trans-9
18:1, HT11 and HT10 for 24 h.1
Fatty acid t9-18:1 HT112 HT102 SEM3
TAG
Σt-18:1 51.55a 35.80b 50.65a 1.649
t6–t8-18:1 0.00b 1.35ab 2.56a 0.530
t9-18:1 51.55a 2.13bc 3.38b 0.555
t10-18:1 0.00b 1.88b 37.69a 1.318
t11-18:1 0.00c 22.41a 3.87b 0.695
t12-18:1 0.00c 3.11a 1.12b 0.092
t13/t14-18:1 0.00c 2.17a 1.23b 0.090
t15-18:1 0.00c 2.01a 0.65b 0.082
t16-18:1 0.00b 0.74a 0.16b 0.057
Σc9,t-18:2 0.00a 11.87b 2.02c 0.695
c9,t13-/c9,t14-18:2 0.00c 1.28a 0.66b 0.120
t6,c9-18:2 0.00b 0.23a 0.03b 0.042
c9,t15/c9,t12-18:2 0.00b 0.97a 0.28b 0.077
c9,t11-18:2 0.00b 8.82a 1.04b 0.711
PL
Σ t-18:1 34.11a 19.11b 26.68c 0.854
t6–t8-18:1 0.00a 0.61b 1.55c 0.040
t9-18:1 34.11a 1.64bc 2.75b 0.454
t10-18:1 0.00b 0.47b 18.21a 0.461
t11-18:1 0.00c 11.63a 2.07b 0.379
t12-18:1 0.00c 1.78a 0.68b 0.064
t13/t14-18:1 0.00c 1.25a 0.78b 0.049
t15-18:1 0.00c 1.21a 0.43b 0.071
t16-18:1 0.00c 0.52a 0.21b 0.031
Σ c9,t-18:2 0.00a 14.30b 3.57c 0.481
c9,t13-/c9,t14-18:2 0.00c 1.71a 1.08b 0.061
t6,c9-18:2 0.00b 0.43a 0.10b 0.032
c9,t15/c9,t12-18:2 0.00c 1.21a 0.39b 0.060
c9,t11-18:2 0.00b 10.36a 2.00c 0.447
a-c Means within a row not sharing common letters are significantly different
(Po0.05).
1 c¼cis; t ¼trans; c9,t-18:2¼Δ9 desaturation products of t-18:1 isomers.
2 HT11¼beef t-18:1 fraction enriched with t11-18:1; HT10¼beef t-18:1 fraction
enriched with t10-18:1.
3 Standard error of the mean.
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Fig. 2. Effect of culturing HepG2 cells with 100 mM of cis(c)9-18:1, trans(t)9-18:1,
HT11 or HT10 on relative mRNA expression of genes related to fatty acid (FA)
synthesis (ACC: acetyl-CoA carboxylase, FAS: fatty acid synthase), Δ9 desaturation
(SCD1: Stearoyl-CoA desaturase-1), cholesterol synthesis (HMGCR: 3-Hydroxy-3-
Methylglutaryl-CoA reductase), transcriptional regulation of lipogenesis (SREBP1c:
sterol regulatory element-binding protein-1c) and cholesterol synthesis (SREBP2:
sterol regulatory element-binding protein-2). Values (mean7SE; n¼6/treatment)
are expressed as fold changes relative to the control. Within each gene, symbol ‘*’
denotes significant (Po0.05) up-regulation against BSA control (no fatty acid).
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Increasing HT11 concentration from 100 mM to 200 mM did not
affect HepG2 cell viability, but viability was reduced in a dose
dependent manner by HT10 and t9-18:1, and effects were more
accentuated in HT10 treated cells. Trans 18:1 fatty acids have been
shown to induce cell death by both caspase-dependent (e.g.activation of caspase-3, -7 and -9) and caspase-independent
pathways (e.g autophagy and intracellular reactive oxygen pro-
duction) [28–30]. Most previous studies treated cells with t9-18:1,
but effects of other t18:1 isomers on cell viability have not been
extensively studied. In primary cardiac myofibroblasts both t9-
18:1 and t11-18:1 reduced cell growth [28], while in HepG2 cells,
t11-18:1 had less adverse effects than t9-18:1 on cell viability [19].
The reason for the greater cytotoxicity of HT10 than t9-18:1 in the
current study is not known. To our knowledge there is no previous
study on the effects of t10-18:1 on cell viability, but early studies in
rats fed PHVO (i.e. containing a broad spectrum of t18:1 isomers)
showed that among t18:1 isomers, t10-18:1 was selectively ex-
cluded from PL of tissues, which might be related to its potent
cytotoxic properties [31]. Further studies are required to explain
the cytotoxic effects of t10-18:1.
The reduced content of SFA and cis-MUFA in TAG and PL of cells
treated with t9-18:1, HT10, and HT11 is likely due to their sub-
stitution with t18:1 isomers [19]. The increased SCD1 index (c9-
16:1/16:0 ratio) in the PL fraction related to incubation with t9-
18:1 or HT10 (compared to c9-18:1 and HT11) is consistent with
up-regulation of SCD1 activity, which is responsible for introdu-
cing a double bond between carbon 9 and 10 [32]. Interestingly,
culturing with t9-18:1 or HT10 increased the c9-16:1/16:0 ratio in
PL but not in TG. This could be due to the fact that PL are an im-
portant component of cell membranes and upregulation of SCD1
(which leads to increased Δ9 desaturation indices) has been
suggested to be a defence mechanism used by the cells to restore
membrane fluidity when high levels of saturated and trans fatty
acids are present [33,34]. The lack of increase in SCD1 expression
(and SCD1 indices) in cell treated with HT11 could be related to
the fact that a significant portion of t18:1 isomers in HT11 un-
derwent Δ9 desaturation, which could increase membrane fluid-
ity, and some SCD1 products (e.g. c9,t11-18:2) are known to pro-
vide negative feedback to reduce SCD1 expression [34,35]. The
dramatic increase in the c9-18:1/18:0 ratio in c9-18:1 treated cells
was likely because of the addition of exogenous c9-18:1 rather
than increased Δ9 desaturase activity.
The greater accumulation of t18:1 into TG and PL fractions of
HepG2 cells treated with HT10 or t9-18:1 could also be related in
part to the fact that t9-18:1 and t10-18:1 cannot undergo Δ9 de-
saturation due to the position of the trans double bond [36,37]. In
contrast, a significant portions of t18:1 in HT11 (e.g. t11-, t12-, t13/
14- and t15-18:1) underwent Δ9 desaturation giving rise to their
desaturation products including c9,t11-18:2, c9,t12-/c9,t15-18:2
and c9,t13-/c9,t14-18:2, and these were incorporated to a greater
extent in PL than TG.
Consistent with our results, c9,t11-18:2 was selectively accu-
mulated in liver PL of pigs fed a commercial conjugated linoleic
acid mixture [38]. In contrast to 18:2n-6, which is located pre-
dominantly at the sn-2 position of PL, conjugated 18:2 isomers
that contain one cis and one trans double bond (e.g. c9,t11-18:2
and t10,c12-18:2) are known to be selectively incorporated at the
sn-1 position, demonstrating the influence of the trans double
bond on the positional distribution of its parent molecule [39].
Furthermore, the incorporation of c9,t11-18:2 at the sn-1 position
of PL is suggested to increase membrane fluidity since they mainly
replace SFA (e.g. 16:0 and 18:0) which typically occupy the sn-1
position of PL [39]. Thus, Δ9 desaturation of t18:1 that can un-
dergoΔ9 desaturation might to some extent alleviate the reduced
membrane fluidity caused by their parent molecules. For example,
the insertion of a cis double bond in t11-18:1 by SCD1 reduces the
melting point from 44 °C to 4.5 °C [40]. As a consequence, the
extent of Δ9 desaturation of t18:1 isomers might have important
health implications. Interestingly, the content of t9-18:1 and t10-
18:1 (that do not undergo Δ9 desaturation) in the platelets of
patients with coronary artery disease have been significantly
P. Vahmani et al. / Biochemistry and Biophysics Reports 7 (2016) 84–90 89correlated with the extent of the disease, while no associations
were found with t11- or t12-18:1 which can undergo Δ9 desa-
turation [41]. In addition, the anti-carcinogenic and anti-athero-
genic properties of t11-18:1 have been mainly related to its con-
version to c9,t11-18:2 [42]. However, the potential health effects of
Δ9 desaturation products of other t-18:1 isomers have not been
studied or considered.
Consistent with previous studies using liver cells [18,19], we
observed t9-18:1 increased the expression of genes involved in
fatty acid synthesis (FAS), Δ9 desaturation (SCD1), cholesterol
synthesis (HMGCR) as well as key transcriptional regulators of li-
pogenesis (SREBP1c) and cholesterol synthesis (SREBP2). We are,
however, the first to observe gene expression effects of HT10 are
similar to t9-18:1, except for SREBP1c, which only tended to be
upregulated by HT10.
Lipogenic genes including FAS and SCD1 are SREBP1 target
genes, while HMGCR, the rate limiting enzyme for cholesterol
synthesis, is mainly a target gene of SREBP-2 [43,44]. Recently
Shao and Ford [18] reported an increased expression and activity
of SREBP-1c in HuH-7 cells cultured with t9-18:1. Increased ex-
pression of SREBP-1c target genes (ACC, FAS and SCD1) were then
also detected, and authors concluded increased hepatic lipogen-
esis caused by t9-18:1 is mainly mediated by an SREBP-1c de-
pendent mechanism. Similarly, the upregulation of HMGCR by t9-
18:1 could be mediated via SREBP-2. Although we did not measure
the SREBP protein or activity in the current study, the greater
mRNA expression of SREBP-1c and SREBP2 in cells treated with t9-
18:1 and HT10 could in part explain the increased expression of
lipogenic genes (e.g, FAS and SCD1) and HMGCR. The increased
expression of key genes involved in hepatic cholesterol and fatty
acid synthesis suggests an increased capacity of liver cells for
synthesis of fatty acids and cholesterol needed for VLDL formation
(the precursor for LDL). It will now be important to determine
whether the in vitro effects of HT10 will parallel the in vivo effects
on lipogenesis, lipoprotein metabolism and blood cholesterol (e.g.
increased LDL-cholesterol and the LDL-cholesterol/HDL-choles-
terol ratio).
In contrast to t9-18:1 and HT10, culturing cells with HT11 did
not affect the expression of any measured genes compared to
control or c9-18:1. The muted effect of HT11 on lipogenic gene
expression in HepG2 cells could be explained in part by the con-
version of t11-18:1 (the major isomer in HT11) to c9,t11-18:2
which has been shown to decrease hepatic SREBP-1c mRNA ex-
pression and activity resulting in decreased hepatic lipogenesis
in vivo [45]. Consistent with this, feeding t11-18:1 has been shown
to decrease hepatic lipogenesis and improve blood lipid profiles in
animal models of dyslipidemia and metabolic syndrome [46–49],
which have been mainly associated with its endogenous conver-
sion to c9,t11-18:2. Effects of Δ-9 desaturation products of other
t18:1 isomers, however, remain unknown.5. Conclusion
The effects of 18:1 isomers on HepG2 cell viability were de-
pendent on double bond position and geometric configuration. All
18:1 isomers resulted in reduced cell viability relative to control.
Both c9-18:1 and HT11were the least toxic, t9-18:1 had dose re-
sponse increased toxicity, and HT10 had the greatest toxicity. Both
t9-18:1 and HT10 increased lipogenic gene expression in liver cells
compared to c9-18:1 and HT11. Overall, results suggest the content
and profile of t-18:1 in foods should be considered when ex-
amining their health effects, and a focus on ruminant-derived
trans fatty acids should be a priority now that they will become
the major source of trans fatty acids in the food supply. Additional
in vivo studies will be required to determine if present results willtranslate into recommendations to increase or curtail consump-
tion of meat and dairy products enriched with either t10-18:1 or
t11-18:1.Acknowledgement
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